4.6 Article

Carbohydrate Sequence of the Prostate Cancer-associated Antigen F77 Assigned by a Mucin O-Glycome Designer Array

Journal

JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 289, Issue 23, Pages 16462-16477

Publisher

AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M114.558932

Keywords

-

Funding

  1. National Institutes of Health [U01 CA128416, U01 CA168925]
  2. NCI Alliance of Glycobiologists
  3. Wellcome Trust [WT093378MA, WT099197MA]
  4. United Kingdom Research Council Basic Technology Initiative Glycoarrays Grant [GRS/79268]
  5. UK Engineering and Physical Sciences Research Council [EP/G037604/1]
  6. China Scholarship Council
  7. Fundacao para a Ciencia e Tecnologia Portugal Grant [BPD SFRH/26515/2006]
  8. EPSRC [EP/G037604/1] Funding Source: UKRI
  9. Engineering and Physical Sciences Research Council [EP/G037604/1, GR/S79268/02] Funding Source: researchfish

Ask authors/readers for more resources

Monoclonal antibody F77 was previously raised against human prostate cancer cells and has been shown to recognize a carbohydrate antigen, but the carbohydrate sequence of the antigen was elusive. Here, we make multifaceted approaches to characterize F77 antigen, including binding analyses with the glycolipid extract of the prostate cancer cell line PC3, microarrays with sequence-defined glycan probes, and designer arrays from the O-glycome of an antigen-positive mucin, in conjunction with mass spectrometry. Our results reveal F77 antigen to be expressed on blood group H on a 6-linked branch of a poly-N-acetyllactosamine backbone. We show that mAb F77 can also bind to blood group A and B analogs but with lower intensities. We propose that the close association of F77 antigen with prostate cancers is a consequence of increased blood group H expression together with up-regulated branching enzymes. This is in contrast to other epithelial cancers that have up-regulated branching enzymes but diminished expression of H antigen. With knowledge of the structure and prevalence of F77 antigen in prostate cancer, the way is open to explore rationally its application as a biomarker to detect F77-positive circulating prostate cancer-derived glycoproteins and tumor cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available